CompletedNCT03558074
Evaluate the Therapeutic Effects and Safety of ALK4290 in Patients With Refractory Wet Age-Related Macular Degeneration
PHASE2 · 26 planned enrolment
- Countries listed
- 1
- Registry update
- December 22, 2020
immortal.lifeTrial registrations containing the exact intervention label ALK4290.
No aliases or equivalent products have been inferred.
This is a registry availability fact, not a safety result, comparison, or conclusion.
Understand the safety boundary →PHASE2 · 26 planned enrolment
PHASE2 · 30 planned enrolment